Macrogenics (MGNX) Tops Q2 EPS by 19c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Macrogenics (MGNX) Tops Q2 EPS by 19c

MacroGenics Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results

August 7, 2018 4:01 PM EDT

ROCKVILLE, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2018.

MacroGenics continues to advance its portfolio of oncology product candidates toward multiple data read-outs, said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. We expect to complete enrollment of the SOPHIA Phase 3 metastatic breast cancer study of margetuximab... More